Subscriber access provided by Northern Illinois University
Article
Molecular mechanism of betaine on hepatic lipid metabolism: Inhibition of FoxO1 binding to PPARg Dae Hyun Kim, Bonggi Lee, Min Hi Park, Min Jo Kim, Hye Jin An, Eun Kyeong Lee, Ki Wung Chung, June Whoun Park, Byung Pal Yu, Jae Sue Choi, and Hae Young Chung J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.6b02644 • Publication Date (Web): 21 Aug 2016 Downloaded from http://pubs.acs.org on August 23, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 26
Journal of Agricultural and Food Chemistry
1 2
Molecular mechanism of betaine on hepatic lipid metabolism: Inhibition of
3
FoxO1 binding to PPARγγ
4 5
Dae Hyun Kim† , Bonggi Lee† , Min Jo Kim†, Min Hi Park†, Hye Jin An†, Eun Kyeong
6
Lee†, Ki Wung Chung†, June Whoun Park†, Byung Pal Yu§, Jae Sue Choi∥, Hae Young
7
Chung†*
8
†
9
Pharmacy, Pusan National University, Busan 609-735, Republic of Korea;
#
#
Molecular Inflammation Research Center for Aging Intervention (MRCA), College of
10
§
11
∥
12
Republic of Korea
Department of Physiology, The University of Texas Health Science Center at San Antonio;
Department of Food and Life Science, Pukyong National University, Busan, 608-737,
13 14
#
These authors contributed equally to this work.
15 16
*To whom all correspondence should be addressed:
17
Prof. Dr. Hae Young Chung
18
Department of Pharmacy, College of Pharmacy, Pusan National University
19
Gumjung-gu, Busan 609-735, Korea
20
Telephone: 82-51-510-2814; Fax: 82-51-518-2821;E-mail:
[email protected] 21 1
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
22 23
ABSTRACT: Betaine is a major water-soluble component of Lycium chinensis. Although
24
there are reports about the protective effects of betaine on hepatic steatosis, the underlying
25
mechanisms are unclear. We used db/db mice and HepG2 cells to examine mechanism
26
underlying betaine-mediated protection against hepatic steatosis. Here, we showed increased
27
hepatic lipid accumulation in db/db mice which is associated with increased activation of
28
lipogenic transcription factors including FoxO1 and PPARγ, whereas betaine administration
29
by oral gavage reversed these characteristics. We investigated whether betaine ameliorates
30
hepatic steatosis by inhibiting FoxO1/PPARγ signaling in HepG2 cells. Although adenovirus-
31
mediated FoxO1 overexpression notably increased mRNA expression levels of PPARγ and its
32
target genes including FAS and ACC, betaine treatment reversed them. Furthermore, betaine
33
inhibited FoxO1 binding to the PPARγ promoter and PPARγ transcriptional activity in
34
HepG2 cells, which was previously shown to induce hepatic steatosis. We concluded that
35
betaine ameliorates hepatic steatosis, at least in part, by inhibiting the FoxO1 binding to
36
PPARγ and their downstream lipogenic signaling cascade.
37 38
Keywords: Betaine; FoxO1; PPARγ; lipogenesis; steatosis
39 40 41 42 43
2
ACS Paragon Plus Environment
Page 2 of 26
Page 3 of 26
Journal of Agricultural and Food Chemistry
44
INTRODUCTION
45
Betaine, an oxidative metabolite of choline, is related to the synthesis of methionine from
46
homocysteine in the liver. Betaine is rich in various foods including wheat bran (13.4mg/g),
47
wheat germ (12.4mg/g), spinich (6mg/g), beets (2.97mg/g), and goji berry (10.1mg/g) (1).
48
Previous studies showed that betaine administration protected the liver from hepatotoxicants,
49
such as ethanol and lipopolysaccharide (LPS), possibly by decreasing oxidative stress (2, 3).
50
A recent study showed that betaine administration reduced fatty liver and increased hepatic
51
insulin signaling in high fat-fed mice (4). However, mechanisms underlying betaine-mediated
52
protection against fatty liver are not fully understood. Thus, it is necessary to examine
53
specific signaling pathways regulated by betaine in order to ameliorate hepatic steatosis.
54
Forkhead box O (FoxO) proteins are evolutionally conserved transcription factors in
55
mammals and include FoxO1, FoxO3a, FoxO4, and FoxO6 (5). Of these, FoxO1 is well-
56
known for its regulatory effects on hepatic lipid metabolism. Studies showed that increased
57
FoxO1 is closely associated with hepatic steatosis. It was reported in an animal study that
58
expression of a constitutively active FoxO1 in liver induced hepatic lipid accumulation
59
arising from elevated lipogenic signaling and reduced fatty acid oxidation (6). Furthermore,
60
a human study indicated that FoxO1 nuclear localization and expression were markedly
61
increased in patients with steatohepatitis (7). In addition, FoxO1 mRAN levels were
62
positively associated with nonalcoholic fatty liver score and were controlled by drug
63
targeting hepatic lipogenesis (7). Thus, FoxO1 may be a key transcription factor that
64
regulates hepatic lipid accumulation.
65
In the current study, we investigated the mechanisms underlying betaine-mediated
66
amelioration of hepatic steatosis in db/db mice. We focused on the inhibitory effects of 3
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
67
betaine on FoxO1 and related lipogenic signaling.
68 69
MATERIALS AND METHODS
70
Materials
71
2',7'-Dichlorodihydrofluorescein diacetate (DCFDA) was obtained from Molecular
72
Probes, Inc. (Carlsbad, CA, USA). Western blotting detection reagents were obtained from
73
Amersham (Chalfont St. Giles, UK). All antibodies examined in our study were purchased
74
from Santa Cruz Biotechnology (Dallas, TX, USA) except p-FoxO1 (Ser 256) (Cell Signaling,
75
Beverly, MA, USA). Anti-rabbit and anti-mouse secondary antibodies were purchased from
76
Amersham Pharmacia Biotech. Anti-sheep/goat secondary antibodies were obtained from
77
Serotec (Oxford, UK).
78 79
Mouse studies
80
C57BLKS/J-db/db mice and their normal littermate C57BLKS/J-db/+ mice (8 weeks old,
81
male) were purchased from Japan SLC (Hamamatsu, Japan). Betaine or control solution was
82
administered to the mice by oral gavage (50 mg/kg/day) for 3 weeks. Body weight and food
83
intake were measured every other day. The mice were housed in cages under a 12 h light and
84
dark cycle at ~24°C and ~50% relative humidity. The mice were sacrificed after 3 weeks.
85
Tissue samples were collected separately and frozen in the nitrogen tank. For long-term
86
storage, the tissue samples were moved to -80°C deep freezer located at Aging Tissue Bank
87
in Pusan National University. For further analysis, tissue samples were sliced on the dry ice.
88
For a glucose tolerance test, mice were fasted overnight. Glucose (2g/kg) was administered 4
ACS Paragon Plus Environment
Page 4 of 26
Page 5 of 26
Journal of Agricultural and Food Chemistry
89
through intraperitoneal cavity and blood was obtained from the tail vein. Glucose
90
concentration was measured by a glucometer (Accu-Chek Active, Roche). All animal studies
91
were designed by the Aging Tissue Bank and approved by the Institutional Animal Care
92
Committee of Pusan National University. We followed the guidelines for animal experiments
93
issued by Pusan National University (Approval Number PNU-2012-0088).
94 95
Cell culture system
96
HepG2 cells were purchased from the ATCC (Rockville, MD, USA) and cultured in the
97
DMEM media (Nissui Co., Tokyo, Japan) supplemented with 10% FBS (Gibco, Grand Island,
98
NY, USA). Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2.
99
Cell viability after treatments was measured by the 3-(4,5-dimethylthiazol-2-Yl)-2,5-
100
diphenyltetrazolium bromide (MTT) assay. For palmitate treatment, palmitate was dissolved
101
in 0.1M NaOH at 70°C. Then, the dissolved palmitate was mixed with 5% BSA solution at
102
60°C.
103 104
Protein fractionation
105
The cultured cells were washed with cold PBS. The cytosolic fraction buffer (10 mM Tris
106
at pH 8.0, 1.5 mM MgCl2, 1 mM dithiothreitol, 0.1% nonidet P-40, and protease inhibitors)
107
was used for isolating the cytosolic fraction of proteins. The nuclear fraction buffer (10 mM
108
Tris at pH 8.0, 50 mM KCl, 100 mM NaCl, and protease inhibitors) was used to isolate the
109
nuclear fraction from the pellet obtained after the cytosolic protein isolation. The protein
110
fractionation was performed by centrifugation at 13,420 g at 4ºC for 15 min. 5
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
111
FoxO1 adenoviral overexpression
112
FoxO1-expressing adenovirus is a kind gift from Dr. H. Henry Dong at University of
113
Pittsburgh School of Medicine. HepG2 cells were transduced with adenoviral vectors at a
114
defined dose of 100 plaque-forming units (pfu) per cell. FoxO1-expressing adenovirus
115
(1.0×1011 pfu/ml) was transduced to HepG2 cells for 24h and the null adenovirus (1.25×1011
116
pfu/ml) was used as a control (8).
117 118
Western Blotting
119
Homogenized samples were boiled for 5 min in gel-loading buffer (125 mM Tris-Cl, 4%
120
sodium dodecyl sulfate (SDS), 10% 2-mercaptoethanol, pH 6.8, 0.2% bromophenol blue) at a
121
volume ratio of 1:1. Total protein-equivalents for each sample were separated by SDS-
122
polyacrylamide gel electrophoresis (PAGE) and transferred to PVDF membranes.
123
Membranes were then incubated with specific primary antibodies at 4ºC overnight, followed
124
by incubation with horseradish peroxidase-conjugated secondary antibodies at 25ºC for 1 h.
125
Western images were visualized by enhanced chemiluminescence according to the
126
manufacturer's instructions. Western blotting images were semi-quantified using the image J
127
software.
128 129
ROS measurements
130
To quantify intracellular ROS generation (9), HepG2 cells were grown in a 96-well plate.
131
After 24 h, the medium was changed to fresh serum-free medium. Cells were pretreated with
132
or without betaine for 3 h followed by treatment with palmitate for 7 h. Then, the medium 6
ACS Paragon Plus Environment
Page 6 of 26
Page 7 of 26
Journal of Agricultural and Food Chemistry
133
was replaced with fresh medium including DCFDA (f.c. 2.5 µM). The fluorescence intensity
134
of DCF was measured every 5 min for 30 min using a microplate fluorescence reader (Tecan,
135
Salzburg, Austria) using excitation and emission wavelengths at 485 and 535 nm, respectively.
136 137
RNA isolation and real time RT-PCR
138
RNA was isolated form 20mg of liver slice or HepG2 cells at ~2x106 concentration using
139
the RNeasy Mini Kit (Qiagen, Hilden, Germany). Real-time PCR was conducted using the
140
Roche LightCycler-RNA amplification kit (Roche Diagnostics, Indianapolis, IN, USA). All
141
the primers were purchased from Integrated DNA Technologies (Coralville, IA, USA). The
142
primer sequences are shown in Supplementary Table 1.
143 144
Chromatin immunoprecipitation (ChIP) and luciferase assays
145
ChIP assays were performed using an EZ ChIP Kit (Millipore) based on the manufacturer's
146
instructions. Luciferase assays were performed using the One-Glo luciferase assay system
147
(Promega, Madison, WI, USA). Detailed methods for ChIP and luciferase assays were
148
shown in our previous publication (10) .
149 150
Statistical Analysis
151
Data are expressed as the mean ± standard error means (SEM). GraphPad Prism 5.0
152
software (GraphPad Software, San Diego, CA) was used for one-way ANOVA followed by
153
Bonferroni post-tests, where p < 0.05 was considered statistically significant. Area under the 7
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
154
curve, a plot of concentration of glucose in blood against time was calculated based on the
155
glucose tolerance test.
156 157
RESULTS
158
Ameliorated glucose tolerance and blood lipid profile in betaine-treated db/db mice
159
Genetically obese db/db mice were used to investigate the effects of betaine on glucose
160
metabolism and the blood lipid profile. As expected, db/db mice exhibited markedly
161
increased body weight due to increased food intake compared to the db/+ control group
162
(Table 1). Furthermore, db/db mice showed highly elevated levels of glucose, insulin,
163
triacylglycerol, and free fatty acids in serum (Fig.1a-b and table 1). A glucose tolerance test
164
showed that serum glucose concentration in db/db mice was maintained much higher than
165
db/+ mice over the whole experimental periods (Fig.1c). These data confirmed that the db/db
166
mice used in our study had obesity-related metabolic syndrome. On the other hand, although
167
body weight and food intake were unaltered (table 1), oral administration of betaine to db/db
168
mice decreased serum glucose level by ~45% (p=0.025), serum insulin level by ~20%
169
(p=0.0098), serum free fatty acid level by ~35% (p=0.032), and serum triacylglycerol level
170
by ~22% (p=0.0087). In addition, betaine treatment decreased glucose intolerance in db/db
171
mice by ~23% based on area under the curve (AUC) of glucose tolerance test (p=0.034).
172
However, no marked differences were observed in adipose tissue weight and liver weight as
173
percentage among groups although kidney weight as percentage was reduced in db/db mice
174
and db/db mice treated with betaine (Table 1). These data suggest that betaine may be helpful
175
for ameliorating obesity-induced dyslipidemia and glucose intolerance and the beneficial
176
effects appear to be independent of changes in energy balance. 8
ACS Paragon Plus Environment
Page 8 of 26
Page 9 of 26
177
Journal of Agricultural and Food Chemistry
Betaine ameliorates hepatic steatosis in db/db mice
178
To examine whether betaine protects liver from obesity-induced lipid accumulation, we
179
measured triacylglycerol content in liver homogenates. Triacylglycerol concentration was
180
increased by ~135% in the liver of db/db mice compared to db/+ mice (p=0.0049), and
181
betaine treatment decreased it by ~38% compared to db/db mice (p=0.00047) (Fig. 2a). ROS
182
generation is closely associated with hepatic lipid accumulation (11). Thus, ROS level was
183
measured in liver homogenates. ROS level was increased by ~260% in the liver of db/db
184
mice compared to that of db/+ mice (p=0.014), and betaine treatment decreased it by ~36%
185
compared to that of db/db mice (p=0.044) (Fig.2b). These data indicate that betaine
186
ameliorated obesity-related hepatic steatosis and oxidative stress.
187 188
Betaine increases insulin signaling and inhibits FoxO1 in liver of db/db mice
189
To examine whether betaine improves insulin signaling in the liver of db/db mice,
190
western blotting was performed to examine the insulin signaling pathway. Compared to the
191
liver of the db/+ control mice, phosphorylation of IRS at Ser307 was increased and
192
phosphorylation of IRS at Tyr 632 was decreased in the liver of db/db mice (Fig. 3a and 3c-
193
3d). However, betaine treatment reversed them to the level comparable to the control group
194
(Fig. 3a and 3c-3d). Consistent with this finding, betaine treatment reversed the reduced
195
phosphorylation of AKT in db/db mice (Fig. 3a and 3e), indicating that betaine increased
196
insulin signaling in the liver of db/db mice. FoxO1, negatively regulated by AKT, has been
197
shown to stimulate lipogenesis, thereby contributing to hepatic steatosis (6, 12). To
198
investigate whether betaine-mediated amelioration of hepatic steatosis is associated with
199
inhibition of FoxO1, we measured the protein levels of FoxO1 and p-FoxO1 and semi9
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
200
quantified and calculated p-FoxO1/FoxO1. Compared to the liver of the control group, p-
201
FoxO1/FoxO1 was decreased in db/db mice, whereas it was significantly increased by
202
betaine treatment (Fig.3b and 3f), indicating that betaine inhibits FoxO1 activation. PPARγ is
203
another lipogenic protein which is involved in hepatic steatosis (13-15). We investigated
204
whether PPARγ is activated in the liver of db/db mice. The protein level of PPARγ was
205
significantly increased in the nucleus fraction of the liver of db/db mice, whereas betaine
206
treatment reversed it (Fig.3b and 3g), indicating that betaine suppresses PPARγ activation.
207
Together, these data suggest that betaine ameliorates hepatic steatosis in db/db mice at least
208
partially trough inhibiting FoxO1 and PPARγ activation.
209 210
Betaine inhibits FoxO1 binding to PPARγ
211
We used a HepG2 liver cell line to investigate further the mechanism underlying
212
betaine-mediated reduction in hepatic steatosis. We first examined whether FoxO1
213
overexpression increases lipid accumulation in HepG2 cells and found that FoxO1 adenoviral
214
overexpression markedly increased triacylglycerol concentration in HepG2 cells (Fig. 4a).
215
Furthermore, FoxO1 overexpression with palmitate treatment additively increased cellular
216
triacylglycerol levels, which was reversed by betaine treatment (Fig.4a). Because palmitate
217
treatment notably increased FoxO1 mRNA (Fig.4b), which was reversed by betaine, we
218
assumed that the protective effect of betaine against lipid accumulation in HepG2 cells is, at
219
least in part, due to inhibition of FoxO1, which was consistent with the in vivo result.
220
Based on the above finding showing betaine-mediated inhibition of FoxO1 and
221
PPARγ in the liver of db/db mice, we investigated whether FoxO1 regulates PPARγ in
222
HepG2 cells and whether betaine affects this process to reduce hepatic steatosis. FoxO1 10
ACS Paragon Plus Environment
Page 10 of 26
Page 11 of 26
Journal of Agricultural and Food Chemistry
223
adenoviral overexpression notably increased mRNA expression of PPARγ and its target genes,
224
such as FAS, acetyl-CoA carboxylase (ACC), and SREBP-1C, which was additively
225
increased by palmitate (Fig. 4b). However, betaine notably decreased mRNA expression of
226
these genes (Fig.4b), indicating that FoxO1 upregulated PPARγ signaling in HepG2 cells,
227
which was inhibited by betaine treatment. To examine whether FoxO1 directly regulates
228
PPARγ transcriptional activity and whether betaine inhibits this process, we performed a
229
PPARγ luciferase assay after palmitate or/and FoxO1 adenovirus treatment. FoxO1
230
significantly increased PPARγ transcriptional activity, which was additively increased by
231
palmitate treatment, and betaine treatment reversed it in HepG2 cells (Fig.4c). In order to
232
examine whether FoxO1 directly binds to PPARγ and whether betaine affects this process in
233
vivo, a ChIP assay was performed using liver homogenates from db/db mice. Interestingly,
234
FoxO1 binding to the PPARγ promoter region was increased in the liver of db/db mice and
235
betaine treatment reversed it to the level comparable to the db/+ control group (Fig. 4d).
236
These data suggest that betaine inhibits the FoxO1 binding to PPARγ, leading to the reduced
237
lipogenic gene expression.
238 239
DISCUSSION
240
It has been reported that betaine improves hepatic insulin signaling and fatty liver,
241
although the underlying mechanisms remain to be elucidated (4, 16, 17). Here, we examined
242
the molecular mechanism by which betaine ameliorates hepatic steatosis using obese db/db
243
mice and HepG2 cells. Our data showed that betaine improved obesity-induced glucose
244
intolerance and hepatic steatosis without altering energy balance. We found that the decreased
245
protein levels of pAKT/AKT and pFoxO1/FoxO1 in db/db mice were recovered by betaine 11
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
246
treatment. In addition, the obesity-induced increase in protein or mRNA expression levels of
247
PPARγ and its downstream genes related to lipogenesis were markedly reduced by betaine
248
treatment.
249
this binding was increased in liver of db/db mice but decreased in the liver of betaine-treated
250
db/db mice. Our in vitro studies showed that FoxO1 directly increased PPARγ promoter
251
activity as well as its target gene expression, and betaine treatment decreased them. Together,
252
our study suggests that the inhibition of FoxO1 binding to PPARγ followed by decreased
253
lipogenic gene expression contributes to betaine-mediated amelioration of hepatic steatosis.
As a potential mechanism, FoxO1 can directly bind to the PPARγ promoter, and
254
It is well documented that PPARγ stimulates hepatic lipid accumulation (13-15, 18).
255
Increased PPARγ expression is closely associated with hepatic steatosis in genetically and
256
diet-induced obese mice by increasing lipogenic gene expression (13, 14, 18). On the other
257
hand, liver-specific deletion of PPARγ in db/db mice markedly ameliorated hepatic steatosis
258
by downregulating FAS, SCD1, and ACC (15). Although various studies reported that both
259
FoxO1 and PPARγ stimulated hepatic steatosis, the relationship between PPARγ and FoxO1
260
in liver is unclear. Our data showed that FoxO1 directly binds to the PPARγ promoter, and
261
this binding was highly increased in hepatic steatosis, which is possibly associated with
262
increased PPARγ expression after FoxO1 overexpression. Furthermore, FoxO1 increased
263
PPARγ transcriptional activity based on the peroxisome proliferator responsive element
264
(PPRE) luciferase assay, indicating that FoxO1 not only increases PPARγ transcription
265
possibly by direct binding to the promoter, but also increases PPARγ activity. These data also
266
indicate that the FoxO1-mediated increase in PPARγ activity at least partially contributes to
267
the increase in hepatic lipid accumulation.
268
Betaine has been shown to increase insulin signaling and ameliorate fatty liver (4). 12
ACS Paragon Plus Environment
Page 12 of 26
Page 13 of 26
Journal of Agricultural and Food Chemistry
269
However, it is unclear how betaine-mediated protection of insulin signaling is associated with
270
the amelioration of fatty liver. Because FoxO1 is phosphorylated and inactivated by AKT, we
271
investigated whether betaine-mediated protection of hepatic steatosis is associated with
272
FoxO1 regulation. In the liver of db/db mice, betaine treatment increased insulin signaling,
273
which is consistent with a previous report (4). In parallel with this, FoxO1 was deactivated by
274
betaine in the liver of db/db mice. Interestingly, betaine notably decreased FoxO1 adenovirus-
275
mediated increase in mRNA expression of lipogenic genes, such as PPARγ, ACC, and FAS in
276
HepG2 cells, suggesting that betaine may inhibit FoxO1-mediated lipogenesis in liver.
277
Because adenoviral FoxO1 overexpression increased mRNA expression of PPARγ and its
278
target genes, which is closely related to hepatic steatosis, we examined whether betaine
279
directly inhibits FoxO1 binding to PPARγ. Data showed that betaine markedly inhibited
280
FoxO1 binding to the PPARγ promotor in the liver of db/db mice. In addition,
281
FoxO1/palmitate-induced PPARγ-PPRE luciferase activity was decreased by betaine
282
treatment in HepG2 cells. Taken together, these data suggest that betaine inhibits FoxO1-
283
mediated up-regulation of PPARγ expression and activity, which partially contributes to
284
betaine-mediated amelioration of hepatic steatosis.
285
Although the betaine-mediated inhibition of FoxO1 binding to PPARγ contributes to the
286
reduction in hepatic steatosis by betaine, it is not the only mechanism underlying the decrease
287
in hepatic steatosis because hyperglycemia and hyperinsulinemia are ameliorated by betaine.
288
It has been shown that hyperglycemia and hyperinsulinemia contributes to hepatic steatosis
289
directly increasing de novo lipogenesis and indirectly by increasing free fatty acids flux to the
290
liver through reduced inhibition of lipolysis (19). Therefore, it is also possible that betaine-
291
mediated improvement of hyperglycemia and hyperinsulinemia also contributes to the
292
decrease in the hepatic steatosis in db/db mice. Because FoxO1 is regulated by insulin 13
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
293
signaling, further studies are necessary to investigate whether increased insulin signaling is
294
an upstream factor to reduce FoxO1 binding to PPARγ.
295
Together, our study revealed that FoxO1 is able to bind to and increase PPARγ activity,
296
which was markedly inhibited by betaine treatment. Thus, we conclude that inhibiting FoxO1
297
binding to PPARγ may be a partial mechanism underlying betaine-mediated protection
298
against hepatic steatosis.
299 300
AUTHOR INFORMATION
301
Corresponding Author: Hae Young Chung
302
Telephone: 82-51-510-2814; Fax: 82-51-518-2821;E-mail:
[email protected] 303 304
NOTE
305
The authors have no conflict of interest to disclose
306 307
ACKNOWLEDGMENTS
308 309
This work was supported by a 2-Year Research Grant of Pusan National University. We also thank the Aging Tissue Bank (Busan, Korea) for supplying research materials.
310 311
REFERENCES
312
1.
313
containing compounds and betaine in common foods. J Nutr 2003, 133, 1302-7.
314
2.
315
Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats.
316
J Nutr 2003, 133, 2845-8.
Zeisel, S. H.; Mar, M. H.; Howe, J. C.; Holden, J. M., Concentrations of choline-
Barak, A. J.; Beckenhauer, H. C.; Mailliard, M. E.; Kharbanda, K. K.; Tuma, D. J.,
14
ACS Paragon Plus Environment
Page 14 of 26
Page 15 of 26
Journal of Agricultural and Food Chemistry
317
3.
318
hepatotoxicity by betaine or taurine in rats. Food Chem Toxicol 2002, 40, 545-9.
319
4.
320
T.; French, S. W.; Morgan, T. R., Betaine improves nonalcoholic fatty liver and associated
321
hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J
322
Physiol Gastrointest Liver Physiol 2010, 299, G1068-77.
323
5.
324
shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004,
325
380, 297-309.
326
6.
327
FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 2006, 116,
328
2464-72.
329
7.
330
M.; Lattuada, E.; Roviaro, G.; Fargion, S., Increased expression and activity of the
331
transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 2008, 57, 1355-62.
332
8.
333
Dong, H. H., FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in
334
mice. J Clin Invest 2008, 118, 2347-64.
335
9.
336
K. W.; Lee, E. K.; An, H. J.; Ullah, S.; Chun, P.; Moon, H. R.; Chung, H. Y., (2R/S,4R)-2-
337
(2,4-Dihydroxyphenyl)thiazolidine-4-carboxylic acid prevents UV-induced wrinkle formation
338
through inhibiting NF-kappaB-mediated inflammation. J Dermatol Sci 2015, 79, 313-6.
339
10.
340
Chun, P.; Moon, H. R.; Chung, H. Y., Potent anti-diabetic effects of MHY908, a newly
Kim, S. K.; Kim, Y. C., Attenuation of bacterial lipopolysaccharide-induced
Kathirvel, E.; Morgan, K.; Nandgiri, G.; Sandoval, B. C.; Caudill, M. A.; Bottiglieri,
Van Der Heide, L. P.; Hoekman, M. F.; Smidt, M. P., The ins and outs of FoxO
Matsumoto, M.; Han, S.; Kitamura, T.; Accili, D., Dual role of transcription factor
Valenti, L.; Rametta, R.; Dongiovanni, P.; Maggioni, M.; Fracanzani, A. L.; Zappa,
Kamagate, A.; Qu, S.; Perdomo, G.; Su, D.; Kim, D. H.; Slusher, S.; Meseck, M.;
Lee, B.; Moon, K. M.; Son, S.; Yun, H. Y.; Han, Y. K.; Ha, Y. M.; Kim, D. H.; Chung,
Park, M. H.; Park, J. Y.; Lee, H. J.; Kim, D. H.; Park, D.; Jeong, H. O.; Park, C. H.;
15
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
341
synthesized PPAR alpha/gamma dual agonist in db/db mice. PLoS One 2013, 8, e78815.
342
11.
343
injury. J Clin Invest 2004, 114, 147-52.
344
12.
345
H. H., Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.
346
Endocrinology 2006, 147, 5641-52.
347
13.
348
2012, 2012, 912351.
349
14.
350
Y.; Saito, H.; Kohgo, Y.; Okumura, T., Increased expression of PPARgamma in high fat diet-
351
induced liver steatosis in mice. Biochem Biophys Res Commun 2005, 336, 215-22.
352
15.
353
Brewer, B., Jr.; Reitman, M. L.; Gonzalez, F. J., Liver-specific disruption of PPARgamma in
354
leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest
355
2003, 111, 737-47.
356
16.
357
Keach, J.; Cave, M.; Chen, T.; McClain, C. J.; Lindor, K. D., Betaine for nonalcoholic fatty
358
liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50, 1818-26.
359
17.
360
E.; Brosnan, J. T., Betaine supplementation prevents fatty liver induced by a high-fat diet:
361
effects on one-carbon metabolism. Amino Acids 2015, 47, 839-46.
362
18.
363
M. S.; Gonzalez, F. J.; Reddy, J. K., Adipocyte-specific gene expression and adipogenic
364
steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1
Browning, J. D.; Horton, J. D., Molecular mediators of hepatic steatosis and liver
Qu, S.; Altomonte, J.; Perdomo, G.; He, J.; Fan, Y.; Kamagate, A.; Meseck, M.; Dong,
Ables, G. P., Update on ppargamma and nonalcoholic Fatty liver disease. PPAR Res
Inoue, M.; Ohtake, T.; Motomura, W.; Takahashi, N.; Hosoki, Y.; Miyoshi, S.; Suzuki,
Matsusue, K.; Haluzik, M.; Lambert, G.; Yim, S. H.; Gavrilova, O.; Ward, J. M.;
Abdelmalek, M. F.; Sanderson, S. O.; Angulo, P.; Soldevila-Pico, C.; Liu, C.; Peter, J.;
Deminice, R.; da Silva, R. P.; Lamarre, S. G.; Kelly, K. B.; Jacobs, R. L.; Brosnan, M.
Yu, S.; Matsusue, K.; Kashireddy, P.; Cao, W. Q.; Yeldandi, V.; Yeldandi, A. V.; Rao,
16
ACS Paragon Plus Environment
Page 16 of 26
Page 17 of 26
Journal of Agricultural and Food Chemistry
365
(PPARgamma1) overexpression. J Biol Chem 2003, 278, 498-505.
366
19.
367
nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006, 91, 4753-61.
Utzschneider, K. M.; Kahn, S. E., Review: The role of insulin resistance in
368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386
17
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 18 of 26
387 388 389 390 391
Table 1. Ameliorated serum lipid profile without changes in energy balance in db/db mice
392
treated with betaine
393
db/+
db/db
db/db+betaine
Body Weight (kg)
25.10 ± 2.17
44.98 ± 3.78***
45.66 ± 3.41
Epididymal fat (%)
6.48 ± 0.31
6.97 ± 0.69
6.00 ± 0.34
Liver (%)
8.79 ± 0.38
9.16 ± 0.64
7.69 ± 0.46
Kidney (%)
0.69 ± 0.02
0.44 ± 0.01**
0.43 ± 0.04**
Food Intake (g/day)
2.96 ± 0.13
5.74 ± 0.31***
5.37 ± 0.19
FFA (mEq/l)
232.00 ± 26.08
400.00 ± 47.27**
259.50 ± 21.36#
Triacylglycerol (ug/ml)
56.80 ± 11.08
88.20 ± 2.16*
69.40 ± 5.46##
394 395 396
Each value is the mean ± SEM (n=5/each group) *
p< 0.05,
**
p< 0.01,
***
p< 0.001, vs. db+ mice; #p< 0.05, ##p< 0.01 vs. db/db mice.
397 398 399 400
18
ACS Paragon Plus Environment
Page 19 of 26
Journal of Agricultural and Food Chemistry
401 402 403 404 405
Figure legends
406
Figure 1. Ameliorated glucose tolerance and blood lipid profile in betaine-treated db/db
407
mice. Betaine (50 mg/kg/day) was administered into db/db mice by oral gavage for 3 weeks.
408
Serum (a) glucose and (b) insulin levels were measured after 3 weeks of betaine
409
administration. (c) Oral glucose tolerance test was performed after 2 weeks of betaine
410
administration. (d) Area under the curve, a plot of concentration of glucose in blood against
411
time was calculated based on the Fig.1c. The results are shown as a bar graph. The data are
412
expressed as a mean ± SEM (n=5).
413
db/db mice.
***
p < 0.001 vs. db+ mice. #p < 0.05 and ##p < 0.01 vs.
414 415
Figure 2. Betaine ameliorates hepatic steatosis and ROS level in db/db mice.
416
(a) ROS level and (b) triacylglycerol concentration in liver were quantified using the
417
DCFHDA method and colorimetric assay kit, respectively after administrating betaine to
418
mice for 3 weeks. The data are expressed as a mean ± SEM (n=5). *p < 0.05 and **p < 0.01
419
vs. db/+ mice. #p < 0.05 and ###p < 0.001 vs. db/db mice.
420 421
Figure 3. Betaine increases insulin signaling and inhibits forkhead box O1 (FoxO1) in
422
liver of db/db mice. Western blotting was performed to examine protein levels of (a) p-
423
insulin receptor substrate (IRS) (Ser307), p-IRS (Tyr623), IRS, p-AKT, and AKT in the
424
insulin signaling pathway in the cytosol fraction of liver of db/db mice treated with betaine.
425
β-actin was used as a loading control for the cytosolic fraction. (b) Protein levels of p-FoxO1,
426
FoxO1, and peroxisome proliferator-activated receptor gamma (PPARγ) related to lipid 19
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
Page 20 of 26
427
accumulation in the nucleus fraction of liver of db/db mice treated with betaine. Histone H1
428
was used as a loading control for the nucleus fraction. (c-g) Western blotting images were
429
semi-quantified using the image J software. Three independent experiments were performed
430
and similar results were obtained.
431 432
Figure 4. Betaine inhibits FoxO1 binding to PPARγ
433
HepG2 cells were pre-treated with betaine for 3 h followed by FoxO1 adenovirus or/and
434
palmitate treatment for 24 h. (a) Cellular triacylglycerol concentration was measured by a
435
colorimetiric assay. (b) Real-time PCR analysis was performed for measuring mRNA levels
436
of sterol regulatory element binding protein 1c (SREBP-1c), fatty acid synthase (FAS),
437
acetyl-CoA carboxylase (ACC), PPARγ, and FoxO1. (c) PPARγ- peroxisome proliferator
438
responsive element (PPRE) luciferase assay was performed to examine whether betaine
439
inhibits PPARγ transcriptional activity. (d) Chromatin immunoprecipitation (ChIP) assay was
440
performed using liver samples of db/db mice to investigate whether betaine inhibits binding
441
of FoxO1 to the PPARγ promoter. The data are expressed as a mean ± SEM. Three
442
independent experiments were performed and similar results were obtained. *p < 0.05, **p